

James B Wetmore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7841776/publications.pdf>

Version: 2024-02-01

99
papers

2,778
citations

257450

24
h-index

197818

49
g-index

99
all docs

99
docs citations

99
times ranked

3581
citing authors

#	ARTICLE	IF	CITATIONS
1	US Renal Data System 2020 Annual Data Report: Epidemiology of Kidney Disease in the United States. <i>American Journal of Kidney Diseases</i> , 2021, 77, A7-A8.	1.9	325
2	Serum Trimethylamine-N-Oxide is Elevated in CKD and Correlates with Coronary Atherosclerosis Burden. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 305-313.	6.1	323
3	Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>European Heart Journal</i> , 2018, 39, 2314-2325.	2.2	186
4	Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. <i>Clinical Epidemiology</i> , 2017, Volume 9, 267-277.	3.0	155
5	Effects of Cinacalcet and Concurrent Low-Dose Vitamin D on FGF23 Levels in ESRD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 110-116.	4.5	136
6	US Renal Data System 2021 Annual Data Report: Epidemiology of Kidney Disease in the United States. <i>American Journal of Kidney Diseases</i> , 2022, 79, A8-A12.	1.9	121
7	Clinical Outcomes after Parathyroidectomy in a Nationwide Cohort of Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 90-97.	4.5	119
8	The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. <i>Kidney International</i> , 2012, 81, 469-476.	5.2	81
9	A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM). <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1031-1040.	4.5	70
10	Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1021-1030.	4.5	65
11	Polycystic Kidney Disease and Cancer after Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2014, 25, 2335-2341.	6.1	59
12	Atrial fibrillation and risk of stroke in dialysis patients. <i>Annals of Epidemiology</i> , 2013, 23, 112-118.	1.9	55
13	The incidence, prevalence, and outcomes of glomerulonephritis derived from a large retrospective analysis. <i>Kidney International</i> , 2016, 90, 853-860.	5.2	50
14	Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?. <i>Nature Clinical Practice Nephrology</i> , 2009, 5, 24-33.	2.0	49
15	Initial Effects of COVID-19 on Patients with ESKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1444-1453.	6.1	45
16	Old versus new: Progress in reaching the goals of the new kidney allocation system. <i>Human Immunology</i> , 2017, 78, 9-15.	2.4	41
17	COVID-19 and kidney disease: insights from epidemiology to inform clinical practice. <i>Nature Reviews Nephrology</i> , 2022, 18, 485-498.	9.6	36
18	The ABCs of Cardioprotection in Dialysis Patients: A Systematic Review. <i>American Journal of Kidney Diseases</i> , 2009, 53, 457-466.	1.9	34

#	ARTICLE	IF	CITATIONS
19	Relationship between Stroke and Mortality in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 80-89.	4.5	33
20	Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation. <i>Stroke</i> , 2020, 51, 2364-2373.	2.0	33
21	Stroke and the "Stroke Belt" in Dialysis: Contribution of Patient Characteristics to Ischemic Stroke Rate and Its Geographic Variation. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 2053-2061.	6.1	30
22	Changes in secondary hyperparathyroidism-related biochemical parameters and medication use following parathyroidectomy. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 103-111.	0.7	30
23	Clinical characteristics and risk factors associated with mortality in calcific uremic arteriolopathy. <i>International Urology and Nephrology</i> , 2017, 49, 2247-2256.	1.4	29
24	Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England. <i>BMC Nephrology</i> , 2019, 20, 85.	1.8	28
25	Factors Associated With Withdrawal From Maintenance Dialysis: A Case-Control Analysis. <i>American Journal of Kidney Diseases</i> , 2018, 71, 831-841.	1.9	27
26	Insights From the 2016 Peer Kidney Care Initiative Report: Still a Ways to Go to Improve Care for Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2018, 71, 123-132.	1.9	25
27	Geographic Variation in Cardioprotective Antihypertensive Medication Usage in Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2011, 58, 73-83.	1.9	24
28	Trends in Anemia Management Practices in Patients Receiving Hemodialysis and Peritoneal Dialysis: A Retrospective Cohort Analysis. <i>American Journal of Nephrology</i> , 2015, 41, 354-361.	3.1	24
29	Risk of hyperkalemia from renin-angiotensin-aldosterone system inhibitors and factors associated with treatment discontinuities in a real-world population. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 826-839.	0.7	22
30	Apixaban versus Warfarin for Treatment of Venous Thromboembolism in Patients Receiving Long-Term Dialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 693-702.	4.5	20
31	Elevated FGF23 Levels Are Associated with Impaired Calcium-Mediated Suppression of PTH in ESRD. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E57-E64.	3.6	19
32	Improving Outcomes in Patients Receiving Dialysis: The Peer Kidney Care Initiative. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1297-1304.	4.5	19
33	Geovariation in Fracture Risk among Patients Receiving Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1413-1421.	4.5	18
34	Apixaban Dosing Patterns Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation Receiving Dialysis: A Retrospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2022, 80, 569-579.e1.	1.9	18
35	Meeting the World's Need for Maintenance Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2601-2603.	6.1	17
36	COVID-19-Associated Decline in the Size of the End-Stage Kidney Disease Population in the United States. <i>Kidney International Reports</i> , 2021, 6, 2698-2701.	0.8	17

#	ARTICLE	IF	CITATIONS
37	Changes in Treatment of Patients with Incident ESKD during the Novel Coronavirus Disease 2019 Pandemic. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2948-2957.	6.1	17
38	Association of Slow Graft Function with Long-Term Outcomes in Kidney Transplant Recipients. <i>Annals of Transplantation</i> , 2018, 23, 224-231.	0.9	17
39	Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage?. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 198-205.	0.7	16
40	Race, Ethnicity, and State-by-State Geographic Variation in Hemorrhagic Stroke in Dialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 756-763.	4.5	16
41	Increases in institutionalization, healthcare resource utilization, and mortality risk associated with Parkinson disease psychosis: Retrospective cohort study. <i>Parkinsonism and Related Disorders</i> , 2019, 68, 95-101.	2.2	15
42	CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin. <i>American Journal of Kidney Diseases</i> , 2021, 78, 180-189.e1.	1.9	15
43	Readmissions Following a Hospitalization for Cardiovascular Events in Dialysis Patients: A Retrospective Cohort Study. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	14
44	Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study. <i>BMC Endocrine Disorders</i> , 2019, 19, 89.	2.2	14
45	Relative Incidence of Acute Adverse Events with Ferumoxytol Compared to Other Intravenous Iron Compounds: A Matched Cohort Study. <i>PLoS ONE</i> , 2017, 12, e0171098.	2.5	12
46	Managing hyperparathyroidism in hemodialysis: role of etelcalcetide. <i>International Journal of Nephrology and Renovascular Disease</i> , 2018, Volume 11, 69-80.	1.8	12
47	International collaborative efforts to establish kidney health surveillance systems. <i>Kidney International</i> , 2020, 98, 812-816.	5.2	12
48	Discrepancies between creatinine- and cystatin C-based equations: Implications for identification of chronic kidney disease in the general population. <i>Scandinavian Journal of Urology and Nephrology</i> , 2010, 44, 242-250.	1.4	11
49	Relationship between calcium channel blocker class and mortality in dialysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1249-1258.	1.9	11
50	Association between higher rates of cardioprotective drug use and survival in patients on dialysis. <i>Research in Social and Administrative Pharmacy</i> , 2015, 11, 824-843.	3.0	11
51	The role of parathyroidectomy in the management of secondary hyperparathyroidism. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 516-522.	2.0	11
52	The Healthy People 2020 Objectives for Kidney Disease: How Far Have We Come, and Where Do We Need to Go?. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 200-209.	4.5	11
53	Impact of a modified data capture period on Liu comorbidity index scores in Medicare enrollees initiating chronic dialysis. <i>BMC Nephrology</i> , 2013, 14, 51.	1.8	10
54	Early withdrawal and non-€withdrawing death in the months following hemodialysis initiation: A retrospective cohort analysis. <i>Hemodialysis International</i> , 2019, 23, 261-272.	0.9	10

#	ARTICLE	IF	CITATIONS
55	A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution. <i>Statistics in Medicine</i> , 2017, 36, 4121-4140.	1.6	9
56	Adherence to Kidney Disease: Improving Global Outcomes Mineral and Bone Guidelines for Monitoring Biochemical Parameters. <i>American Journal of Nephrology</i> , 2019, 49, 225-232.	3.1	9
57	Estimation of Drug Effectiveness by Modeling Three Time-Dependent Covariates: An Application to Data on Cardioprotective Medications in the Chronic Dialysis Population. <i>Statistics in Biopharmaceutical Research</i> , 2014, 6, 229-240.	0.8	8
58	Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study. <i>Clinical Nephrology</i> , 2017, 88, 254-265.	0.7	8
59	Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis. <i>PLoS ONE</i> , 2018, 13, e0203767.	2.5	8
60	Association of Race with Cumulative Exposure to Statins in Dialysis. <i>American Journal of Nephrology</i> , 2012, 36, 90-96.	3.1	7
61	Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care. <i>BMC Nephrology</i> , 2016, 17, 53.	1.8	7
62	Association of 25-hydroxyvitamin D deficiency with NT-pro BNP levels in patients with acute myocardial infarction: a cross-sectional analysis. <i>BMC Research Notes</i> , 2011, 4, 542.	1.4	6
63	Role of lean body mass in estimating glomerular filtration rate in Alzheimer disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2222-2231.	0.7	6
64	Painless Myocardial Ischemia Is Associated with Mortality in Patients with Chronic Kidney Disease. <i>Nephron Clinical Practice</i> , 2012, 122, 9-16.	2.3	6
65	Outcomes Following Ischemic Stroke in Older Patients With CKD Stages 4 and 5: A Retrospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2020, 76, 784-793.	1.9	6
66	Association of Dementia-Related Psychosis With Long-term Care Use and Death. <i>Neurology</i> , 2021, 96, e1620-e1631.	1.1	6
67	Patient characteristics, disease burden, and medication use in stage 4 and 5 chronic kidney disease patients. <i>Clinical Nephrology</i> , 2016, 85 (2016), 101-111.	0.7	6
68	Catheter-Associated Bloodstream Infections among Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 429-433.	4.5	6
69	Impact of Race on Cumulative Exposure to Antihypertensive Medications in Dialysis. <i>American Journal of Hypertension</i> , 2013, 26, 234-242.	2.0	5
70	Geographic variation of parathyroidectomy in patients receiving hemodialysis: a retrospective cohort analysis. <i>BMC Surgery</i> , 2016, 16, 77.	1.3	5
71	Parathyroidectomy: Complex Decisions about a Complex Procedure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1133-1135.	4.5	5
72	Testing Patterns for CKD-MBD Abnormalities in a Sample US Population. <i>Kidney International Reports</i> , 2021, 6, 1141-1150.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Geographic Variation in HMG-CoA Reductase Inhibitor Use in Dialysis Patients. <i>Journal of General Internal Medicine</i> , 2012, 27, 1475-1483.	2.6	4
74	The association of chronic kidney disease with the use of renin-angiotensin system inhibitors after acute myocardial infarction. <i>American Heart Journal</i> , 2015, 170, 735-743.	2.7	4
75	Factors Associated with Elective Withdrawal of Maintenance Hemodialysis: A Case-Control Analysis. <i>American Journal of Nephrology</i> , 2020, 51, 227-236.	3.1	4
76	Sequential Bone Scintigraphy and the Evolution of Warfarin-Mediated Calcific Uremic Arteriopathy. <i>Case Reports in Nephrology and Dialysis</i> , 2021, 11, 78-86.	0.6	4
77	Association of Decreased Glomerular Filtration Rate with Racial Differences in Survival after Acute Myocardial Infarction. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 733-740.	4.5	3
78	Calcimimetics: A Promise Unfulfilled. <i>American Journal of Kidney Diseases</i> , 2020, 76, 308-310.	1.9	3
79	Pragmatic clinic randomized trial to improve chronic kidney disease care: Design and adaptation due to COVID disruptions. <i>Contemporary Clinical Trials</i> , 2021, 109, 106501.	1.8	3
80	An ensemble survival model for estimating relative residual longevity following stroke: Application to mortality data in the chronic dialysis population. <i>Statistical Methods in Medical Research</i> , 2017, 26, 2667-2680.	1.5	2
81	Relation of Race, Apparent Disability, and Stroke Risk With Warfarin Prescribing for Atrial Fibrillation in Patients Receiving Maintenance Hemodialysis. <i>American Journal of Cardiology</i> , 2019, 123, 598-604.	1.6	2
82	Understanding the Burden of the COVID-19 Pandemic for People With Kidney Disease. <i>American Journal of Kidney Diseases</i> , 2021, 78, 777-779.	1.9	2
83	Adverse Outcomes Associated With Off-Label Agents Used to Treat Dementia Patients With Psychosis: A Case-Control Medicare Database Study. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2022, 37, 153331752210813.	1.9	2
84	CKD Biomarkers, Cognitive Impairment, and Incident Dementia in an Older Healthy Cohort. <i>Kidney360</i> , 2022, 3, 435-445.	2.1	2
85	The rise of FGF23: should insights from population-based studies inform future clinical trials?. <i>Kidney International</i> , 2016, 90, 477-479.	5.2	1
86	Association of multiple ischemic strokes with mortality in incident hemodialysis patients: an application of multistate model to determine transition probabilities in a retrospective observational cohort. <i>BMC Nephrology</i> , 2016, 17, 134.	1.8	1
87	Dialysis and End-Stage Kidney Disease. , 2019, , 311-338.e4.		1
88	Response by Wetmore et al to Letter Regarding Article, "Direct-Acting Oral Anticoagulants Versus Warfarin in Medicare Patients With Chronic Kidney Disease and Atrial Fibrillation". <i>Stroke</i> , 2020, 51, e363-e364.	2.0	1
89	Development and outcomes of hyperkalemia in hospitalized patients: potential implications for care. <i>American Heart Journal</i> , 2021, 241, 59-67.	2.7	1
90	Changes in hemodialysis catheter management after introduction of the end-stage renal disease prospective payment system. <i>BMC Nephrology</i> , 2021, 22, 8.	1.8	1

#	ARTICLE	IF	CITATIONS
91	Authors'™ Reply. Journal of the American Society of Nephrology: JASN, 2022, 33, 455.2-457.	6.1	1
92	Oral Paricalcitol. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2006, 5, 326-327.	1.8	0
93	Infections Requiring Hospitalization in Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2101-2103.	4.5	0
94	Association of hospital transfusion use and infection-related rehospitalizations among patients receiving hemodialysis: A retrospective cohort study. Hemodialysis International, 2020, 24, 79-88.	0.9	0
95	Review: Insufficient evidence exists on the benefit of vitamin D in patients with chronic kidney disease not requiring dialysis. Annals of Internal Medicine, 2010, 152, JC4.	3.9	0
96	Low Quality of International Classification of Diseases, 10th Revision, Procedural Coding System Data Undermines the Validity of the Standardized Transfusion Ratio: Time to Chart a New Course?. Advances in Chronic Kidney Disease, 2019, 26, 237-249.	1.4	0
97	Secondary Hyperparathyroidism and Hyperphosphatemia. Nephrology Self-assessment Program: NephSAP, 2020, 19, 206-214.	3.0	0
98	Economic Evaluation of Healthcare Resource Utilization and Costs for Newly Diagnosed Dementia-Related Psychosis. Geriatrics (Switzerland), 2022, 7, 29.	1.7	0
99	Medicare claims analysis of agents used to manage dementia-related psychosis: a treatment pattern study. International Clinical Psychopharmacology, 2022, 37, 84-91.	1.7	0